With embargoed data put into play long before the weekend's ASCO presentations, there was little surprise when ImClone's positive new data for Erbitux underscored the insiders' disappointment with the news. Adding Erbitux to a first-line colon cancer therapy reduced the risk of new tumor growth by 15 percent, but patients still didn't do as well as those taking Avastin. Wall Street's conclusion: With data like that, Erbitux won't be winning any significant new market share. Of course, insiders had this data some time ago, raising fresh doubts about the way that ASCO distributes the data in advance of the meeting.
- read this report on Erbitux from TheStreet.com
Related Articles:
ImClone buoyed by new Erbitux data. Report
Erbitux data could gin extra $350M in sales. Report
Analysts raise doubts on Erbitux ruling. Report
ImClone touts survival rate in Erbitux cancer trial. Report